High-throughput screening (HTS) has grown rapidly in the past decade, with many advances in new assay formats, detection technologies, and laboratory automation. Recently, several studies have shown that the choice of assay technology used for the screening process is particularly important and can yield quite different primary screening outcomes. However, because the screening assays in these previous studies were performed in a single-point determination, it is not clear to what extent the difference observed in the screening results between different assay technologies is attributable to inherent assay variability and day-to-day measurement variation. To address this question, a nuclear receptor coactivator recruitment assay was carried out in 2 different assay formats, namely, AlphaScreen™ and time-resolved fluorescence resonance energy transfer, which probed the same biochemical binding events but with different detection technologies. For each assay format, 4 independent screening runs in a typical HTS setting were completed to evaluate the run-to-run screening variability. These multiple tests with 2 assay formats allow an unambiguous comparison between the discrepancies of different assay formats and the effects of the variability of assay and screening measurements on the screening outcomes. The results provide further support that the choice of assay format or technology is a critical factor in HTS assay development. (Journal of Biomolecular Screening 2005:581-589) 
INTRODUCTION
M ANY BIOLOGICALLY AND PHARMACOLOGICALLY ACTIVE substances are discovered by testing either focused or randomly collected chemical libraries. 1 Driven by combinatorial and parallel chemical synthesis and genomic-based target discovery, high-throughput screening (HTS) has grown rapidly in the past decade into an active field in drug discovery, with many advances in new assay formats, detection technologies, and automation. [1] [2] [3] With the capability of screening a million or more compounds in a matter of weeks, the screening process itself is no longer a bottleneck in drug discovery. However, despite the significant increase in screening throughput achieved during the past several years, a concern has arisen that this increase in throughput had not led to a concomitant increase in the number of new development candi-dates that have originated from HTS. 4 The attrition of lead compounds due to bioavailability and toxicology issues is one of the major causes. 5 This issue is being addressed by integrating ADME/toxicity assays earlier into the drug discovery process. Some other important factors in HTS processes that may affect the efficiency in hit-to-lead optimization include assay methodology and assay quality used in HTS, availability of suitable counterscreens, and drug likeness of compound collection. In an attempt to address some of these challenges and concerns in HTS, studies have been initiated to address quality aspects of the screening process. One of the first of these studies established a parametric statistic, the Z′ factor, to evaluate assay quality in screening. 6 Since then, increasing attention has been placed on quality assessment during assay development and validation, quality control during screening, and postscreening data analysis for hit identification. Furthermore, studies have begun to address the question of whether similar or comparably active compounds are identified from the same chemical library using different assay technologies. [7] [8] [9] [10] [11] [12] Currently, there are usually many choices of assay formats available for various types of biological targets in developing HTS assays. Results from several recent studies reveal that different assay and detection technologies can generate quite different hit lists for the same biochemical interaction. 7, 8, 10, 11 However, because all these previous comparison studies were carried out by evaluating each compound in a single determination in primary screening, this raises the critical question of how much of the observed various difference in the identified primary hits between different assay formats is attributable to the data variability associated with the single determination in the primary screen.
In an attempt to address this question, we evaluated in this study a subset of approximately 25,000 randomly selected compounds in a nuclear receptor coactivator recruitment assay, using 2 different assay technologies, AlphaScreen™ and time-resolved fluorescence resonance energy transfer (TR-FRET). In principle, both assay formats probe the same biochemical interaction. A series of 4 independent runs was completed for each assay technology. The data collected from the screening were analyzed to evaluate the assay and run-to-run screening variability and to compare that to the differences of the hits from the 2 assay formats. The results of this study indicate that the selection of assay formats is a critical factor of consideration in HTS assay development.
MATERIALS AND METHODS

Materials
Rat farnesoid X receptor (FXR) DNA coding for the ligandbinding domain (amino acids 215 through 469, Genbank U18374) was inserted into plasmid pGEX-4T-3 (27-4583-01; Amersham Pharmacia, Piscataway, NJ) as a fusion protein with glutathione Stransferase (GST). Expression and purification of the fusion protein GST-FXR was performed as described previously. 13 A biotinylated 25-aa peptide derived from human nuclear receptor coactivator SRC-1 (amino acids 676 through 700, Genbank U90661) with sequence Biotin-CPSSHSSLTERHKILHRLL QEGSPS was chemically synthesized and purified using standard methods. The FXR agonist, chenodeoxycholic acid (CDCA), and all other chemicals were purchased from Sigma (St. Louis, MO). For the AlphaScreen™ assay, streptavidin-conjugated donor beads and anti-GST antibody-conjugated acceptor beads were purchased from Packard BioSignal (a division of Perkin Elmer; 6760603M; Montreal, Canada). For TR-FRET assay, LANCE ® reagent Eu-W1024-labeled anti-GST antibody was also purchased from Perkin Elmer (AD0065), and allophycocyanin (APC)labeled streptavidin was obtained from Prozyme (PJ25S; San Leandro, CA).
AlphaScreen™ assay for FXR antagonist screening
The AlphaScreen™ assay was developed and the compound screening was carried out as previously described. 8, 13 In brief, 10 µl/well of freshly diluted compound (10 µM; unless specified, all concentrations in parenthesis are final concentrations) was first transferred into white, solid 384-well plates (Nunc, 264572; Rochester, NY) using a Tomtec Quadra 384™ liquid dispenser (1 compound/well). Compounds were then incubated with 10 µl/well of a mixture of GST-FXR fusion protein (0.5 nM), biotinylated SRC-1 coactivator peptide (5 nM), and AlphaScreen™ anti-GST antibody conjugated acceptor bead (10 µg/ml). After incubation for 30 min, 10 µl/well of a 2nd mixture, which consisted of CDCA (50 µM) and AlphaScreen™ streptavidin conjugated donor bead (2 µg/ml), was added to initiate the binding. After 2 h incubation at room temperature, the plates were read on an AlphaQuest™ reader (Packard BioSignal). Due to the light-sensitivity of the AlphaScreen™ beads, every step of the reagent addition and final reading was carried out under dim light.
TR-FRET assay for FXR antagonist screening
The TR-FRET assay was performed as previously described. 8, 13 In brief, 10 µl/well of freshly diluted compound was transferred into black 384-well plates (Costar, 3710; Acton, MA) using a Tomtec Quadra 384™ liquid dispenser (1 compound/well). Subsequently, 10 µl/well of a mixture of GST-FXR (0.5 nM), biotinylated SRC-1 peptide (5 nM), streptavidin conjugated APC (2 nM), and europium-labeled anti-GST antibody (1 nM) were added to each well and incubated with the compound. After 30 min, 10 µl/well of CDCA (50 µM) was added to the reaction mixture. The plates were centrifuged briefly and incubated for 2 h at room temperature and were then read twice on a Victor-2™ reader (Perkin-Elmer) to measure fluorescent signals from both APC (665 nm) and europium (615 nm). A ratio of APC and europium fluorescence was calculated for data analysis.
RESULTS
We have previously shown that the overlap of hits when comparing the screening results using different assay technologies is quite low. 7, 8 In an effort to delineate the effect of the inherent assay variability in the primary screen on the difference in identified hits between assay formats, we tested a set of compounds in 4 separate runs in single-point determination, in a nuclear receptor binding assay using either the AlphaScreen™ or TR-FRET assay technologies. A total of 24,640 compounds were randomly selected from the Novartis synthetic compound library and used in this study. The receptor and coactivator peptide used in the assay were kept at the same concentrations in both assay formats. The same liquidhandling instruments and procedures were used for the replicate experiments. There were no obvious patterns on any of the assay plates, and therefore the raw data were normalized to percentage inhibition activity without any data filtering and correction, avoiding any potential pitfalls from the data manipulation.
The activity distribution of each run is shown in Figure 1 . The 4 runs using the AlphaScreen™ technology are referred to as A1, A2, A3, and A4. Similarly, the replicate runs carried out using TR-FRET are referred to as T1, T2, T3, and T4. The assay quality for all of the runs was high, as indicated by the Z′ factor values, which ranged from 0.79 to 0.83 for AlphaScreen™ and 0.84 to 0.85 for TR-FRET assay format. The signal-to-background ratio (S/B) of 17 to 27 was obtained for AlphaScreen™, and an S/B of 8 to 9 was obtained for TR-FRET assays. As seen in Figure 1 , the quadruplicate runs of the same assay format generated similar activity distri-butions. However, the activity distributions of the 2 assay technologies displayed significantly different profiles. For the AlphaScreen™ screening data, the standard deviation (SD) of the compound activity distribution for the 4 experiments in terms of calculated percentage activity (% inhibition) ranged from 11.4 to 14.5, with the 2nd run (A2) having the highest SD (14.5). In comparison, the distribution SD for the TR-FRET screening was significantly lower, ranging from 5.6 to 6.7 in percentage inhibition ( Fig. 1) .
To compare the screening data obtained between the 2 assay technologies, correlations of data from intra-assay and inter-assay runs were calculated. To compare intra-assay data variability, 2 assay runs using AlphaScreen™ (A3 vs. A4) were selected, and their results are plotted in Figure 2A . Similarly, 2 runs with TR-FRET (T3 vs. T4) were selected for comparison, as shown in Figure 2B . There was a significant intra-assay format data correlation for AlphaScreen™ (r = 0.59; p < 0.01) when all the data points were included in the calculation. For the TR-FRET assays, a better correlation was observed (r = 0.78; p < 0.01). In contrast to these results, a low correlation (r = 0.12) was observed between the results for the TR-FRET (T4 run) and AlphaScreen™ (A4 run) assays, as shown in Figure 2C . To further confirm the low correlation results in Figure 2C , the average activity of each compound from the 4 independent measurements (by taking the average, the activities for most compounds will be close to their "real" activities) was calculated for both assay technologies and plotted in Figure 2D . The results again showed that the correlation between the 2 assay formats was low (r = 0.17).
One pragmatically important aspect for comparison of data from different runs and different assay technologies is to compare the number of active compounds (hits) obtained from these screening processes. The hit threshold can be defined in several ways to identify hits from the screening data. For example, the hit threshold or hit limit in HTS can be set at a certain percentage of activity, or a certain number of SDs away from the sample mean values, or a certain percentage of most active compounds out of the total compounds screened. From Figure 1 and Figure 2 , it became clear that the AlphaScreen™ and TR-FRET assay formats generated quite different activity distribution profiles, even though the same positive and negative control conditions were used for activity normalization. For different runs in the same assay format, however, very similar activity profiles were obtained in both assay formats. These results suggest that different assay technologies have different intrinsic data variability and sensitivity or that different assays may have responded to interfering compounds differently (see the Discussion section). Table 1 shows the screening results when the hit limit was set at 3 SD, 4 SD, and 5 SD away from the mean sample inhibition val- ues. In the 4 replicate experiments of the AlphaScreen™ runs, 148, 98, 156, and 144 hits were identified when the hit criterion was set at 3 SD (with percentage inhibition at 43.4, 47.8, 36.5, and 40.4, respectively), with an average of 136.5 ± 26.1 (Average±SD). At the same hit criterion, the number of hits identified from the TR-FRET screening runs ranged from 114 to 159, with an average of 144.7 ± 20.7. Table 1 also includes the number of hits shared with any 2 independent runs within the same assay technologies as well as between the 2 assay formats. Although the number of primary hits in AlphaScreen™ runs (136.5 hits on average) and TR-FRET runs (average of 144.7 hits) are generally close, there is a distinct difference between the degree of hit overlap of the intra-assay runs and that of the inter-assay runs. For example, at a hit limit of 3 SD, the shared (overlapped) hits between any 2 AlphaScreen™ runs ranged from 68 to 103, with an average of 85.5 ± 15.7. For TR-FRET runs at the same hit limit of 3 SD, the shared hits ranged from 81 to 125, with average values 101.5 ± 20.0. In other words, the shared primary hits between any 2 TR-FRET runs are about 70% (101.5 shared/144.7 average total) and between any 2 AlphaScreen™ runs are about 63% (85.5 shared/136.5 average total). In comparison, at the same hit limit criterion, the number of shared hits between 1 AlphaScreen™ run and 1 TR-FRET run ranged from 27 to 59, with an average of only 44.0 ± 9.7 shared hits. This means that only about 31% (i.e., [44.0 × 2]/[136.5 + 144.7]) of the primary hits were shared between any 2 runs of different assay technologies. At hit limits of higher stringency (e.g., 4 SD or 5 SD), this general trend still holds. As seen in Table 1 , the number of shared hits between 2 independent runs of the same as- Correlation of compound inhibition activities between different runs is illustrated to analyze assay reproducibility and technology difference. Two selected different runs in the same assay technology of AlphaScreen™ (A), time-resolved fluorescence resonance energy transfer (TR-FRET) (B), or 2 runs in different assay technologies, AlphaScreen™ versus TR-FRET (C) were shown. For simplification, only 1 correlation example is presented for each situation. Similar to (C), the correlation for average activity from the 2 assay formats is shown in (D). The data from all the compounds were included in the correlation calculation.
Primary Hit Comparison
say format was significantly higher than the number of shared hits between 2 independent runs of different assay formats. Specifically, the average shared hits at 4 SD were 69% for TR-FRET, 63% for AlphaScreen™, and 36% between 2 runs of different assay technologies. At 5 SD, these values became 71%, 53%, and 19%, respectively. A closer look into the number of primary hits from each of the quadruplicate runs with the same format reveals that although the overall assay quality (e.g., with comparable Z′ factors) for these runs was about the same, certain runs generated fewer or larger number of hits than did other replicate runs. For example, at a 3 SD hit cutoff, the A1, A3, and A4 runs generated similar hits, whereas the A2 run generated about 50 fewer (or~30% less) hits than the other 3 runs did. In TR-FRET runs, the T1 run generated about 40 fewer (or~25% less) hits than the other 3 runs did (Table 1) . A subsequent analysis shows that the A2 run and T1 run had a higher false-negative rate than the other corresponding runs. 14 These different screening results in replicate runs reflect the effect of day-today or run-to-run variations of the screening process.
In addition to the percentage activity or standard deviation from the mean, the percentage of compounds screened (hit rate) can also be used to define the hit threshold. Screening results using hit rates of 0.3%, 0.2%, and 0.1% are summarized in Table 2 . For both assay formats, the selected hit rates translate into 74, 50, and 25 hits, respectively. The numbers of shared hits were analyzed in a similar fashion as when the hit limit was set by SD values. Between any 2 TR-FRET runs, the shared hits averaged 52.8 (71% overlap), 31 (62% overlap), and 13.3 (53% overlap) for the top 0.3%, 0.2%, and 0.1% hits, respectively. For AlphaScreen™ runs, these values became 50.3 (68% overlap), 34.8 (70% overlap), and 16 (64% overlap), respectively. These results indicate that for both assay formats, roughly two-thirds of the hits are overlapped (shared) between any 2 runs with the same assay format. In contrast, only about one-third of the hits overlapped (shared) when comparing any 2 runs between the different assay formats, which was significantly below that observed within the same assay format ( Table 2) .
To further investigate the overlapped hits between the 2 assay technologies used in this study, data generated from the multiple screening runs were analyzed to determine the degree of overlap between hits found from the 2 assay technologies at different hitcollection stringencies. The degree of overlap between the 2 assay technologies is shown in Figure 3 , where hits were designated when being "active" at least once in the 4 runs (Figs. 3A, 3C ) or being confirmed active (i.e., active in 3 or all 4 runs; Figs. 3B, 3D) .
The results indicate that, generally, the degree of overlap of hits identified from the AlphaScreen™ and TR-FRET assays was relatively low, as obtained under several hit criteria or at different stringencies of the hit criteria ( Fig. 3) . Notably, when using hit rate as the hit limit criterion, the hit overlap between the 2 assay technologies dwindles down as the hit threshold set to a higher activity. This trend of lower degree of overlap for higher stringency cutoff can also be seen when various numbers of the most active compounds from each assay format are considered. The average percentage inhibition activity value obtained from all 4 runs of each assay format was calculated for each compound and used to rank the compound's overall activity. These results are shown in Figure A1  148  66  23  A2  68  98  24  34  8  11  A3  98  72  156  47  28  73  14  10  36  A4  98  74  103  144  45  27  49  61  13  11  19  24   T1  T2  T3  T4  T1  T2  T3  T4  T1  T2  T3 Figure 4 , the degree of overlap decreased steadily as the compound's activity increased and the selected hit number decreased.
DISCUSSION
Recently, assay comparison studies in HTS 7, 8 have indicated that there is a relatively low degree of overlap of identified active compounds for the same biochemical target when different assay technologies are used. Because the primary screening was carried out as a single-point test for each compound in these previous studies, it is impossible to evaluate the exact causes of the low degree of hit overlaps. To evaluate the concordance of 2 quantitative assays, repeated measurements are needed. 15 Without a doubt, the variability of the measurement could contribute, to a certain extent, to the differences in active compounds identified by different assay technologies. By screening in replicate determinations, the major cause of the discrepancy in the observed screening results reported previously can be addressed as to whether it was mainly attributable to the use of different assay technologies or due to assay and run-to-run measurement variability. In this study, the same biological target was independently screened 4 times in 2 different assay formats, AlphaScreen™ and TR-FRET, and the screening results were analyzed and compared in several ways. The results show that when the same hit criteria (whether set as percentage activity, SD from the mean, or hit rate) were used, the overlap of active compounds identified between the 2 different assay technologies remained fairly low, whereas the overlap of hits from the screening runs of the same assay format are dramatically higher. In addition, when the same number of the most active compounds (e.g., top 0.5%) were compared from screening in the 2 different assay formats, the number of shared hits (Fig. 4) was also significantly lower than the number of shared hits between 2 separate runs within the same assay format. These results indicate that, at least in the current study, the assay and run-to-run data measurement variability is not the main contributing factor to the large discrepancies between the identified hits from the 2 assay formats. Instead, it is possible that the discrepancy is mainly caused by the use of different assay detection technologies. Replicate testing with the same assay format will improve the hit confirmation rate and reduce the false-positive and false-negative hit rates caused by measurement variability, 14 but it will not alleviate the assay methodologyspecific limitations and artifacts. Although this is only a case study and its indication cannot be blindly generalized to every assay type, this study presents supportive evidence to the previous findings that different assay technologies can lead to significantly different outcomes from screening. 7, 8 However, for assays with lower quality (larger data variability), the assay measurement error would have an increased impact on the screening results.
The disparity of identified screening hits is possibly due to compound interference with specific assay detection technologies by perturbing the detection signal or hindering essential molecule- A1  74  50  25  A2  45  74  32  50  13  25  A3  50  49  74  33  38  50  12  19  25  A4  53  50  55  74  36  34  36  50  14  19  19  25   T1  T2  T3  T4  T1  T2  T3  T4  T1  T2  T3 
Between format runs T1  28  15  14  17  14  9  9  12  7  5  3  5  T2  20  13  13  21  15  8  8  12  5  4  3  5  T3  16  19  19  27  13  10  10  15  5  4  5  6  T4  27  16  20  28  15  9  11  16  5  5  6  7 molecule interactions on which the detection method is based. On the other hand, each assay technology might be limited in identifying certain structural classes, such that a specific assay technology might be capable of identifying certain classes of hits while missing other classes, which would lead to the occurrence of false negatives. Possible mechanisms for these limitations of hit finding for each assay format may include the sensitivity and responsiveness of the detection system, the relative concentration of the assay components, perturbation of the drug-binding site conformation by the assay technology, or compound interference. All these mechanisms could lead to a limited hit-finding capability for a given assay format. For FXR coactivator recruitment assays in the current study, a counterscreening system using biotinylated GST is useful for detecting compound interference. Even though it was not implemented in the current study, counterscreening was carried out during a previous comparison study with the same 2 assay formats. 8 From that study, we found that hits identified in the TR-FRET assay format had little compound interference, whereas a small number of compounds interfered with the AlphaScreen™ assay signal, possibly due to quenching of singlet oxygen molecules (data not shown). However, it was found that compound interference for the AlphaScreen™ assay alone could not explain the disparity in screening hits. Whether assay interference is the major contributor of screening hit discrepancy remains a question that deserves further investigation. In addition, it will be very useful to analyze and compare the physical and chemical properties (such as fluorescence/ultraviolet absorbance properties) of overlapped or unoverlapped hits between the 2 assay formats.
One assumption commonly made in HTS is that although some weak hits may sometimes be missed from a screening program, the most potent compounds will always be identified, regardless of which assay format or detection technology is used. The results from this study indicate that this is not necessarily the case (see Fig.  2D and Fig. 4 ). Although some of the most active hits were indeed found in both assay formats, the overlap of the most active compounds from the 2 assay detection technologies employed in this study was generally less than 50%. In addition, we found that the degree of overlap actually decreased as the hit criteria became more stringent in activity (Fig. 4) . These results could be partly attributed to the possibility that some compounds in the library might interfere directly with specific assay detection technologies. These interfering compounds or assay artifacts can appear as very potent hits and may populate the hit list as the hit criterion moves to higher activity stringency. The results from this study also suggest that a hit criterion set too high could sometimes lead to a biased result, which favors compounds that preferentially interact with an assay technology.
In this FXR coactivator binding assay, most of the key assay conditions, such as the concentrations of the receptor, agonist control, testing compound, coactivator peptide, buffer, and incubation times were identical. Nonetheless, the 2 assay formats generated dramatically different activity profiles for the same compound collection screened (Fig. 1) . Furthermore, the inhibition activities in both formats were normalized against the same positive and negative controls. Therefore, the different activity profiles seen in Figure 1 should reflect the intrinsic differences of the assay formats and detection technologies. Because both screening formats were executed by the same set of liquid-handling devices, the variability differences due to liquid transfer procedures can be largely ruled out. Therefore, the 2 assay formats could either have very different intrinsic assay data variability and/or a very different compound interfering profile. Although the different compound interference of the 2 assay detection methods can possibly contribute to some extent to the inhibition profile difference, it is not trivial to pinpoint the exact effect. On the other hand, the disparity in activity distribution profiles can also be due to the intrinsic data variability of the 2 technologies. Figure 5 plots the data variability of the quadruplicate tests for each compound in the 2 assay formats. It shows that the intrinsic data variability in the AlphaScreen™ format is significantly higher than in the TR-FRET format. Therefore, the difference in activity dispersions of the compound collection observed in AlphaScreen™ and TR-FRET formats (Fig. 1 ) might be mainly caused by the detection technology itself. In AlphaScreen™ technology, the signal is highly amplified during the signal-transfer process in the microspheres (beads), generating greater detection sensitivity. 16 As a result, the amplification process is likely to contribute to a higher degree of variation in the measured signal. In contrast, the TR-FRET assay generates signals with less variability Hit limit Criteria  Top 200  Top 150  Top 100  Top 75  Top 50  Top 25   TR-FRET Sp e c i f i c  1 1 8  9 1 6  6 5  0 3  7 2  1   Overlapped  82  59  34  25  13  4   AlphaScreen Specific  118  91  66  50  37 due to the ratiometric readout (F650 nm/F620 nm) and no signal amplification involved in the energy-transfer process. This article presents our observation and analysis in a typical HTS process of the effects of assay and screening measurement variability and different assay technologies for hit identification. The results suggest that each assay format has its own applicability and limitation in screening, leading to varied degrees of overlapped hits from different assay formats and technologies. The selection of a preferred assay format and a screening strategy for a specific biological target will deserve more consideration in this regard. Multiplexing readouts or using complementary assay formats might be needed for improving the hit-finding capability and efficiency. 
